ClinicalTrials.gg
RecruitingNCT07469527Updated Nov 20, 2026

Effects of Feel Free® Classic Tonic on Stress and Pharmacokinetics in Healthy Adults

An interventional study of Placebo and Kava and Kratom Herbal Supplement in Anxiety, Physiological Stress and Stress, sponsored by Botanic Tonics, LLC. Recruiting at 1 site in Canada. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Botanic Tonics, LLC · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 20, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Study summary

This study is being conducted to assess the effects of the Feel Free® Classic Tonic on stress in healthy adults. The goal is to see whether the tonic can help reduce self-perceived and physiological stress and provide information on how its ingredients are processed in the body.

Read the detailed description

This is a randomized, double-blind, parallel, 3-arm, placebo-controlled study to assess the effects of two dose levels of the Feel Free® Classic Tonic on stress in healthy adults. The primary goal is to evaluate how the tonic affects self-reported and physiological measures of stress and anxiety. A pharmacokinetic sub-study will assess how the tonic's components are absorbed and processed. The tonic contains kava and kratom, botanicals traditionally used for relaxation and mood support, and early data suggest it is generally well tolerated.

02

Conditions studied

  • Anxiety
  • Physiological Stress
  • Stress

Browse trials for

Keywords

  • Stress Control
  • Anxiety
  • Relaxation
03

In context

Anxiety Disorders Unverified

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

This study's planned enrollment of 165 is above the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Botanic Tonics, LLC is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults who are between 21 - 55 years of age (inclusive) at screening.
  2. Have self-reported stress at screening and baseline scoring 14 - 26 (inclusive) on the PSS-10.
  3. In good general health (no uncontrolled diseases or conditions) as deemed by the investigator and is able to consume the study product.
  4. Not currently using, defined as ≤ 3 uses in the past 3 months prior to Baseline, any nicotine containing products (patches, gums, vapes etc.), kava products, and/or kratom products, and willing to abstain starting 14 days prior to Baseline and throughout the study.
  5. Have a range of 18.5 - 29.9 kg/m2 at screening and baseline.
  6. Agree to follow the restrictions on concomitant treatments.
  7. Agree to follow the restrictions on lifestyle.
  8. Have maintained consistent dietary habits, including supplement intake, and lifestyle for the last 3 months before screening and agree to maintain them throughout the study.
  9. Agree to use acceptable methods.
  10. Agree to abstain from alcohol consumption for the entire duration of the study.
  11. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures.
  12. For Sub-Study participants only:

    • Must have suitable veins for repeated venipuncture.
    • Willing and able to attend video conference calls with study coordinators.

Exclusion criteria

Exclusion Criteria:

  1. Individuals who are lactating, planning to become pregnant during the study, or pregnant as confirmed by a positive pregnancy test during study visits.
  2. Have a known sensitivity, intolerability, or allergy to any of the study products, their , or rescue medication.
  3. Demonstrates a positive urine drug screen test for compounds listed in Table 9 Screening or Baseline visits, a positive urine cotinine test at the Screening or Baseline visits, or a positive breath alcohol test at Baseline visit.
  4. Have abnormal RR or SpO2 measurements at Screening or Baseline at the discretion of the investigator.
  5. Screening laboratory results showing liver enzyme levels [ (ALT), Aspartate Transaminase (AST), Alkaline Phosphatase (ALP), Gamma-Glutamyl Transferase (GGT), total ] ≥ 2 times the , or any other abnormal safety laboratory values as per the Investigator's discretion.
  6. Is currently enrolled in another clinical trial or has received/used an product in another research study within 28 days before baseline.
  7. Individuals with an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea).
  8. Have Type I/Type II diabetes or thyroid disease (thyroid function to be assessed by TSH, T3, and T4 levels at Screening visit).
  9. High BP at the Screening or Baseline Visit (≥140 systolic or ≥90 diastolic mmHg)
  10. Have low BP (\<90 systolic or \<60 diastolic mmHg) at Baseline unless deemed clinically insignificant by the investigator and the participant is asymptomatic.
  11. Have a history of heart disease, blood clotting disorders, renal or hepatic impairment/disease, or liver injury.
  12. Have known genetic polymorphisms of CYP450, , CYP2D6, and/or CYP1A2 enzymes.
  13. Individuals with active asthma or have experienced an asthma attack in the last 5 years.
  14. Are receiving treatments for or have been hospitalized in the last 12 months for psychiatric disorders (e.g., depression, bipolar disorder, schizophrenia, etc.).
  15. Have a history of cancer (except localized skin cancer without or in situ cervical cancer) with recovery occurring within 5 years before the screening visit.
  16. Reports significant blood loss or blood donation totaling between 101 mL to 449 mL of blood within 30 days before baseline or a blood donation of more than 450 mL within 56 days before baseline.
  17. Reports donating plasma (e.g., plasmapheresis) within 15 days before baseline.
  18. Major surgery in 3 months before screening or planned major surgery during the study.
  19. History of alcohol or substance abuse (e.g., opioids, kratom) (including having been hospitalized for such an in-patient or out-patient intervention program).
  20. Evidence of addictive tendency as indicated by an LDQ score ≥21.
  21. Use of anxiolytic or sleep aids (natural health products or drugs) in the 4 weeks before baseline.
  22. Currently consumes more than two (2) standard alcoholic beverages per day on average for 4 weeks.

    Note: A standard alcoholic beverage is defined as 12 ounces of beer, 5 ounces of wine, or 1.5 ounces of liquor.

  23. Excessive caffeine intake, defined as habitual consumption of >500 mg per day.
  24. Any other medical conditions or use of medications/supplements/therapies that, in the opinion of the investigator, may adversely affect the participant's ability to complete the study or its measures, pose a significant risk to the participant or compromise the quality of study data.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
165 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    No Active Product per bottle

    Other: Placebo

  • Experimental
    Feel Free Classic Tonic Dose 1

    Active Product of 380 mg Kava root extract and 1480 mg of dried Kratom Leaf powder per bottle

    Other: Kava and Kratom Herbal Supplement

  • Experimental
    Feel Free Classic Tonic Dose 2 (half strength)

    Active Product of 190 mg Kava root extract and 740 mg of dried Kratom Leaf powder per bottle

    Other: Kava and Kratom Herbal Supplement

Interventions

  • OtherPlacebo

    Placebo

  • OtherKava and Kratom Herbal Supplement

    Feel Free Classic Tonic Dose 1 (TP1)

  • OtherKava and Kratom Herbal Supplement

    Feel Free Classic Tonic Dose 2 (TP2 - Half Strength)

06

What researchers measure

Primary outcomes

  1. Change in Perceived Stress Scale-10 (PSS-10) Score

    Change in PSS-10 score from baseline to Day 29 to assess the effect of the test product on self-perceived stress. Items are scored on a 5-point Likert scale ranging from 0 ('Never') to 4 ('Very Often'). Higher scores indicate higher perceived stress levels.

    Time frame: Baseline (Day 1) to Day 29

Secondary outcomes

  1. Change in State-Trait Anxiety Inventory - State (STAI-S) - Single Dose

    Change in STAI-S score from pre-dose to post-dose (pre-Trier Social Stress Test - Arithmetic \[pre-TSST-A\]) on Day 1 after a single dose. The scale assesses how participants feel "right-now". It measures subjective and temporary fluctuations in feelings associated with anxiety. Items (e.g., "I worry too much over something that really doesn't matter", "I am content") are rated on a 4-point scale, such as from "Almost Never" to "Almost Always". Higher score to be a higher anxiety.

    Time frame: Day 1 pre-dose to Day 1 post-dose (pre-TSST-A)

  2. Change in State-Trait Anxiety Inventory - State (STAI-S) During TSST-A (Trier Social Stress Test - Arithmetic) - Single Dose

    Change in STAI-S score from pre-TSST-A to post-TSST-A at 0, 15, 25, and 55 minutes on Day 1. The scale assesses how participants feel "right-now". It measures subjective and temporary fluctuations in feelings associated with anxiety. Items (e.g., "I worry too much over something that really doesn't matter", "I am content") are rated on a 4-point scale, such as from "Almost Never" to "Almost Always". Higher score to be a worse outcome.

    Time frame: Day 1 assessments at pre-TSST-A, and post-TSST-A at 0, 15, 25, 55 minutes

  3. Change in State-Trait Anxiety Inventory - State (STAI-S) - Multiple-Day Dosing

    Change in STAI-S score from pre-dose to post-dose (pre-Trier Social Stress Test - Arithmetic \[pre-TSST-A\]) on Day 29 after a single dose. The scale assesses how participants feel "right-now". It measures subjective and temporary fluctuations in feelings associated with anxiety. Items (e.g., "I worry too much over something that really doesn't matter", "I am content") are rated on a 4-point scale, such as from "Almost Never" to "Almost Always". Higher score to be a worse outcome.

    Time frame: Day 29 pre-dose to Day 29 pre-TSST-A

  4. Change in State-Trait Anxiety Inventory - State (STAI-S) During TSST-A (Trier Social Stress Test - Arithmetic) - Multiple-Day Dosing

    Change in STAI-S score from pre-TSST-A to post-TSST-A at 0, 15, 25, and 55 minutes on Day 29. The scale assesses how participants feel "right-now". It measures subjective and temporary fluctuations in feelings associated with anxiety. Items (e.g., "I worry too much over something that really doesn't matter", "I am content") are rated on a 4-point scale, such as from "Almost Never" to "Almost Always". Higher score to be a worse outcome.

    Time frame: Day 29 measurements at pre-TSST-A, and post-TSST-A at 0, 15, 25 and 55 minutes.

  5. Change in State-Trait Anxiety Inventory - Trait (STAI-T)

    Change in STAI-T score from pre-dose Day 1 to pre-dose Day 29. The scale assesses how respondents feel "generally". It measures relatively stable individual differences in anxiety proneness. Items (e.g., "I worry too much over something that really doesn't matter", "I am content") are rated on a 4-point scale, such as from "Almost Never" to "Almost Always". Higher score to be a higher anxiety.

    Time frame: Day 1 to Day 29

  6. Physiological Stress Markers (Cortisol) - Single Dose

    Change in salivary cortisol (µg/dL) from pre-dose to post-dose (pre-Trier Social Stress Test - Arithmetic \[pre-TSST-A\]) on Day 1.

    Time frame: Day 1

  7. Physiological Stress Markers (Alpha-Amylase) - Single Dose

    Change in alpha-amylase (U/mL) from pre-dose to post-dose (pre-Trier Social Stress Test - Arithmetic \[pre-TSST-A\]) on Day 1

    Time frame: Day 1

  8. Physiological Stress Markers (Cortisol) During Trier Social Stress Test - Arithmetic (TSST-A) - Single Dose

    Change in salivary cortisol (µg/dL) from pre-TSST-A to 10, 20, 30, and 60 minutes post-TSST-A

    Time frame: Day 1

  9. Physiological Stress Markers (Alpha-Amylase) During Trier Social Stress Test - Arithmetic (TSST-A) - Single Dose

    Change in salivary alpha-amylase (U/mL) from pre-TSST-A to 10, 20, 30, and 60 minutes post-TSST-A

    Time frame: Day 1

  10. Physiological Stress Markers (Heart Rate) During Trier Social Stress Test - Arithmetic (TSST-A) - Single Dose

    Change in heart rate (bpm) from pre-TSST-A to 60 minutes post-TSST-A.

    Time frame: Day 1

  11. Physiological Stress Markers (Cortisol) - Multiple-Day Dose

    Change in salivary cortisol (µg/dL) from pre-dose to post-dose (pre-Trier Social Stress Test - Arithmetic \[pre-TSST-A\]) on Day 29.

    Time frame: Day 29

  12. Physiological Stress Markers (Alpha-Amylase) - Multiple-Day Dose

    Change in salivary alpha-amylase (U/mL) from pre-dose to post-dose (pre-Trier Social Stress Test - Arithmetic \[pre-TSST-A\]) on Day 29.

    Time frame: Day 29

  13. Physiological Stress Markers (Cortisol) During Trier Social Stress Test - Arithmetic (TSST-A) - Multiple-Day Dosing

    Change in salivary cortisol (µg/dL) from pre-TSST-A to 10, 20, 30, and 60 minutes post-TSST-A.

    Time frame: Day 29

  14. Physiological Stress Markers (Alpha-Amylase) During Trier Social Stress Test - Arithmetic (TSST-A) - Multiple-Day Dosing

    Change in salivary alpha-amylase (U/mL) from pre-TSST-A to 10, 20, 30, and 60 minutes post-TSST-A

    Time frame: Day 29

  15. Physiological Stress Markers (Heart Rate) During Trier Social Stress Test - Arithmetic (TSST-A) - Multiple-Day Dosing

    Change in heart rate (bpm) from pre-TSST-A to 60 minutes post-TSST-A.

    Time frame: Day 29

  16. Awakening Cortisol Response

    Change in morning awakening salivary cortisol over 30 minutes from baseline to Day 29.

    Time frame: Baseline Day 1 to Day 29

  17. Awakening Alpha-Amylase Response

    Change in morning awakening alpha-amylase over 30 minutes from baseline to Day 29

    Time frame: Baseline Day 1 to Day 29

Other outcomes

  1. PK Profile of Mitragynine AUC0-8 (Single Dose)

    Area under the plasma concentration (AUC) -time curve from 0 to 8 hours after a single dose.

    Time frame: Day 1 (0-8 hours)

  2. PK Profile of Mitragynine AUC8-24 (Single Dose)

    Area under the plasma concentration (AUC)-time curve from 8 to 24 hours after a single dose.

    Time frame: Day 1-Day 2 (8-24 hours)

  3. PK Profile of Mitragynine AUC0-24 (Single Dose)

    Area under the plasma concentration (AUC) -time curve from 0 to 24 hours after a single dose.

    Time frame: Day 1-Day 2 (0-24 hours)

  4. PK Profile of Mitragynine AUC0-∞ (Single Dose)

    Area under the plasma concentration (AUC) -time curve from 0 to infinity after a single dose.

    Time frame: Day 1-Day 2 (0-24 hours)

  5. PK Profile of Mitragynine Cmax (Single Dose)

    Maximum observed plasma concentration (Cmax) after a single dose from 0 to 24 hours.

    Time frame: Day 1-Day 2 (0-24 hours)

  6. PK Profile of Mitragynine Tmax (Single Dose)

    Time to reach maximum observed plasma concentration (Tmax) after a single dose from 0 to 24 hours.

    Time frame: Day 1-Day 2 (0-24 hours)

  7. PK Profile of Mitragynine Half-Life (T½) (Single Dose)

    Terminal elimination half-life after a single dose from 0 to 24 hours.

    Time frame: Day 1-Day 2 (0-24 hours)

  8. PK Profile of Mitragynine Elimination Rate Constant (Kel) (Single Dose)

    Terminal elimination rate constant after a single dose from 0 to 24 hours.

    Time frame: Day 1-Day 2 (0-24 hours)

  9. PK Profile of 7-hydroxymitragynine AUC0-8 (Single Dose)

    Area under the plasma concentration (AUC) -time curve from 0 to 8 hours after a single dose.

    Time frame: Day 1 (0-8 hours)

  10. PK Profile of 7-hydroxymitragynine AUC8-24 (Single Dose)

    Area under the plasma concentration (AUC) -time curve from 8 to 24 hours after a single dose.

    Time frame: Day 1-Day 2 (8-24 hours)

  11. PK Profile of 7-hydroxymitragynine AUC0-24 (Single Dose)

    Area under the plasma concentration (AUC) -time curve from 0 to 24 hours after a single dose.

    Time frame: Day 1-Day 2 (0-24 hours)

  12. PK Profile of 7-hydroxymitragynine AUC0-∞ (Single Dose)

    Area under the plasma concentration (AUC) -time curve from 0 to infinity after a single dose.

    Time frame: Day 1-Day 2 (0-24 hours)

  13. PK Profile of 7-hydroxymitragynine Cmax (Single Dose)

    Maximum observed plasma concentration (Cmax) after a single dose from 0 to 24 hours.

    Time frame: Day 1-Day 2 (0-24 hours)

  14. PK Profile of 7-hydroxymitragynine Tmax (Single Dose)

    Time to reach maximum observed plasma concentration (Tmax) after a single dose from 0 to 24 hours.

    Time frame: Day 1-Day 2 (0-24 hours)

  15. PK Profile of 7-hydroxymitragynine Half-Life (T½) (Single Dose)

    Terminal elimination half-life after a single dose from 0 to 24 hours.

    Time frame: Day 1-Day 2 (0-24 hours)

  16. PK Profile of 7-hydroxymitragynine Elimination Rate Constant (Kel) (Single Dose)

    Terminal elimination rate constant after a single dose from 0 to 24 hours.

    Time frame: Day 1-Day 2 (0-24 hours)

  17. PK Profile of Kavain AUC0-8 (Single Dose)

    Area under the plasma concentration (AUC) -time curve from 0 to 8 hours after a single dose.

    Time frame: Day 1 (0-8 hours)

  18. PK Profile of Kavain AUC8-24 (Single Dose)

    Area under the plasma concentration (AUC) -time curve from 8 to 24 hours after a single dose.

    Time frame: Day 1-Day 2 (8-24 hours)

  19. PK Profile of Kavain AUC0-24 (Single Dose)

    Area under the plasma concentration (AUC) -time curve from 0 to 24 hours after a single dose.

    Time frame: Day 1-Day 2 (0-24 hours)

  20. PK Profile of Kavain AUC0-∞ (Single Dose)

    Area under the plasma concentration (AUC) -time curve from 0 to infinity after a single dose.

    Time frame: Day 1-Day 2 (0-24 hours)

  21. PK Profile of Kavain Cmax (Single Dose)

    Maximum observed plasma concentration (Cmax) after a single dose from 0 to 24 hours.

    Time frame: Day 1-Day 2 (0-24 hours)

  22. PK Profile of Kavain Tmax (Single Dose)

    Time to reach maximum observed plasma concentration (Tmax) after a single dose from 0 to 24 hours.

    Time frame: Day 1-Day 2 (0-24 hours)

  23. PK Profile of Kavain Half-Life (T½) (Single Dose)

    Terminal elimination half-life after a single dose from 0 to 24 hours.

    Time frame: Day 1-Day 2 (0-24 hours)

  24. PK Profile of Kavain Elimination Rate Constant (Kel) (Single Dose)

    Terminal elimination rate constant after a single dose from 0 to 24 hours.

    Time frame: Day 1-Day 2 (0-24 hours)

  25. PK Profile of Dihydrokavain AUC0-8 (Single Dose)

    Area under the plasma concentration (AUC) - time curve from 0 to 8 hours after a single dose.

    Time frame: Day 1 (0-8 hours)

  26. PK Profile of Dihydrokavain AUC8-24 (Single Dose)

    Area under the plasma concentration (AUC) - time curve from 8 to 24 hours after a single dose.

    Time frame: Day 1-Day 2 (8-24 hours)

  27. PK Profile of Dihydrokavain AUC0-24 (Single Dose)

    Area under the plasma concentration (AUC) - time curve from 0 to 24 hours after a single dose.

    Time frame: Day 1-Day 2 (0-24 hours)

  28. PK Profile of Dihydrokavain AUC0-∞ (Single Dose)

    Area under the plasma concentration (AUC) - time curve from 0 to infinity after a single dose.

    Time frame: Day 1-Day 2 (0-24 hours)

  29. PK Profile of Dihydrokavain Cmax (Single Dose)

    Maximum observed plasma concentration (Cmax) after a single dose from 0 to 24 hours.

    Time frame: Day 1-Day 2 (0-24 hours)

  30. PK Profile of Dihydrokavain Tmax (Single Dose)

    Time to reach maximum observed plasma concentration (Tmax) after a single dose from 0 to 24 hours.

    Time frame: Day 1-Day 2 (0-24 hours)

  31. PK Profile of Dihydrokavain Half-Life (T½) (Single Dose)

    Terminal elimination half-life after a single dose from 0 to 24 hours.

    Time frame: Day 1-Day 2 (0-24 hours)

  32. PK Profile of Dihydrokavain Elimination Rate Constant (Kel) (Single Dose)

    Terminal elimination rate constant after a single dose from 0 to 24 hours.

    Time frame: Day 1-Day 2 (0-24 hours)

  33. PK Profile Mitragynine AUC0-8, Steady State (Multiple-Day Dose)

    Area under the plasma concentration (AUC)- time curve from 0 to 8 hours at steady state after multiple-day dosing.

    Time frame: Day 29 (0-8 hours)

  34. PK Profile Mitragynine AUC8-24, Steady State (Multiple-Day Dose)

    Area under the plasma concentration (AUC)- time curve from 8 to 24 hours at steady state after multiple-day dosing.

    Time frame: Day 29-30 (8-24 hours)

  35. PK Profile Mitragynine AUC0-24, Steady State (Multiple-Day Dose)

    Area under the plasma concentration (AUC)- time curve from 0 to 24 hours at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  36. PK Profile Mitragynine AUC0-∞, Steady State (Multiple-Day Dose)

    Area under the plasma concentration (AUC)- time curve from 0 to infinity at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  37. PK Profile Mitragynine Cmax, Steady State (Multiple-Day Dose)

    Maximum observed plasma concentration (Cmax) at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  38. PK Profile Mitragynine Tmax, Steady State (Multiple-Day Dose)

    Time to reach maximum observed plasma concentration (Tmax) at steady state.

    Time frame: Day 29-30 (0-24 hours)

  39. PK Profile Mitragynine Half-Life (T1/2) at Steady State (Multiple-Day Dose)

    Terminal elimination half-life at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  40. PK Profile Mitragynine Elimination Rate Constant (Kel) at Steady State (Multiple-Day Dose)

    Terminal elimination rate constant at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  41. PK Profile 7-hydroxymitragynine AUC0-8, Steady State (Multiple-Day Dose)

    Area under the plasma concentration (AUC)- time curve from 0 to 8 hours at steady state after multiple-day dosing.

    Time frame: Day 29 (0-8 hours)

  42. PK Profile 7-hydroxymitragynine AUC8-24, Steady State (Multiple-Day Dose)

    Area under the plasma concentration (AUC)- time curve from 8 to 24 hours at steady state after multiple-day dosing.

    Time frame: Day 29-30 (8-24 hours)

  43. PK Profile 7-hydroxymitragynine AUC0-24, Steady State (Multiple-Day Dose)

    Area under the plasma concentration (AUC)- time curve from 0 to 24 hours at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  44. PK Profile 7-hydroxymitragynine AUC0-∞, Steady State (Multiple-Day Dose)

    Area under the plasma concentration (AUC)- time curve from 0 to infinity at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  45. PK Profile 7-hydroxymitragynine Cmax, Steady State (Multiple-Day Dose)

    Maximum observed plasma concentration (Cmax) at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  46. PK Profile 7-hydroxymitragynine Tmax, Steady State (Multiple-Day Dose)

    Time to reach maximum observed plasma concentration (Tmax) at steady state.

    Time frame: Day 29-30 (0-24 hours)

  47. PK Profile 7-hydroxymitragynine Half-Life (T1/2) at Steady State (Multiple-Day Dose)

    Terminal elimination half-life at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  48. PK Profile 7-hydroxymitragynine Elimination Rate Constant (Kel) at Steady State (Multiple-Day Dose)

    Terminal elimination rate constant at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  49. PK Profile Kavain AUC0-8, Steady State (Multiple-Day Dose)

    Area under the plasma concentration (AUC)- time curve from 0 to 8 hours at steady state after multiple-day dosing.

    Time frame: Day 29 (0-8 hours)

  50. PK Profile Kavain AUC8-24, Steady State (Multiple-Day Dose)

    Area under the plasma concentration (AUC)- time curve from 8 to 24 hours at steady state after multiple-day dosing.

    Time frame: Day 29-30 (8-24 hours)

  51. PK Profile Kavain AUC0-24, Steady State (Multiple-Day Dose)

    Area under the plasma concentration (AUC)- time curve from 0 to 24 hours at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  52. PK Profile Kavain AUC0-∞, Steady State (Multiple-Day Dose)

    Area under the plasma concentration (AUC)- time curve from 0 to infinity at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  53. PK Profile Kavain Cmax, Steady State (Multiple-Day Dose)

    Maximum observed plasma concentration (Cmax) at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  54. PK Profile Kavain Tmax, Steady State (Multiple-Day Dose)

    Time to reach maximum observed plasma concentration (Tmax) at steady state.

    Time frame: Day 29-30 (0-24 hours)

  55. PK Profile Kavain Half-Life (T1/2) at Steady State (Multiple-Day Dose)

    Terminal elimination half-life at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  56. PK Profile Kavain Elimination Rate Constant (Kel) at Steady State (Multiple-Day Dose)

    Terminal elimination rate constant at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  57. PK Profile Dihydrokavain AUC0-8, Steady State (Multiple-Day Dose)

    Area under the plasma concentration (AUC)- time curve from 0 to 8 hours at steady state after multiple-day dosing.

    Time frame: Day 29 (0-8 hours)

  58. PK Profile Dihydrokavain AUC8-24, Steady State (Multiple-Day Dose)

    Area under the plasma concentration (AUC)- time curve from 8 to 24 hours at steady state after multiple-day dosing.

    Time frame: Day 29-30 (8-24 hours)

  59. PK Profile Dihydrokavain AUC0-24, Steady State (Multiple-Day Dose)

    Area under the plasma concentration (AUC)- time curve from 0 to 24 hours at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  60. PK Profile Dihydrokavain AUC0-∞, Steady State (Multiple-Day Dose)

    Area under the plasma concentration (AUC)- time curve from 0 to infinity at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  61. PK Profile Dihydrokavain Cmax, Steady State (Multiple-Day Dose)

    Maximum observed plasma concentration (Cmax) at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  62. PK Profile Dihydrokavain Tmax, Steady State (Multiple-Day Dose)

    Time to reach maximum observed plasma concentration (Tmax) at steady state.

    Time frame: Day 29-30 (0-24 hours)

  63. PK Profile Dihydrokavain Half-Life (T1/2) at Steady State (Multiple-Day Dose)

    Terminal elimination half-life at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  64. PK Profile Dihydrokavain Elimination Rate Constant (Kel) at Steady State (Multiple-Day Dose)

    Terminal elimination rate constant at steady state after multiple-day dosing.

    Time frame: Day 29-30 (0-24 hours)

  65. Trough Plasma Concentrations Over Time

    To measure trough plasma concentrations of kratom alkaloids and kavalactones during repeated twice-daily dosing, using pre-dose blood samples collected on alternate days over the first 14 days of study product use. This evaluates concentration buildup prior to steady-state attainment.

    Time frame: Days 1-15 (pre-dose trough sampling)

  66. Comparison of Single-Dose vs Steady-State Cmax

    Difference between between single-dose maximum observed plasma concentration (Cmax) on Day 1 and and steady-state Cmax at Day 29 to evaluate systemic accumulation.

    Time frame: Single dose: Day 1 and Day 2 (0-24 hours) Steady State: Day 29 and Day 30 (0-24 hours), Day 31 (48h), Day 36 (168h)

  67. Comparison of Single-Dose vs Steady-State AUC0-8

    Difference between single-dose area under the plasma concentration (AUC0-8) (Day 1) and steady-state AUC0-8 (Day 29) to assess accumulation over the first 8 hours.

    Time frame: Single dose: Day 1 and Day 2 (0-24 hours) Steady State: Day 29 and Day 30 (0-24 hours), Day 31 (48h), Day 36 (168h)

  68. Comparison of Single-Dose vs Steady-State AUC0-24

    Difference between single-dose area under the plasma concentration (AUC0-24) (Day 1 and Day 2) and steady-state AUC0-24 (Day 29 and Day 30) to assess the 24-hour exposure accumulation.

    Time frame: Single dose: Day 1 and Day 2 (0-24 hours) Steady State: Day 29 and Day 30 (0-24 hours), Day 31 (48h), Day 36 (168h)

  69. Perception of Trier Social Stress Test - Arithmetic (TSST-A) Task

    Perception of the task survey at completion of TSST-A on Days 1 and 29. This non-validated questionnaire consists of 4 questions scored from 0 to 100, that assesses the participants feeling of the TSST-A task. Higher scores indicate higher feelings of difficulty and stress.

    Time frame: Day 1 and Day 29

  70. Modified Drug Effects Questionnaire (DEQ)

    To assess the effect of TP on subjective drug effects compared to placebo. This non-validated questionnaire consists of 4 questions scored from 0 to 100, that assesses the participants subjective experience after consuming the TP.

    Time frame: Day 1 and Day 29, post-dose at 55, 85, 95, 110, 120, 150 minutes

  71. Overall Well Being, Health, and Pain

    To assess the effect of TP on overall well-being, health, and pain compared to placebo. This non-validated questionnaire consists of 4 questions scored from 0 to 100, that assesses overall quality of life with questions specifically on physical health and pain. Higher scores indicate better overall well-being, health, and pain.

    Time frame: Day 1 to Days 15, 29, 36

  72. Product Reliance Scale

    To assess the effect of TP on the severity of dependence compared to placebo. A non-validated questionnaire consisting of 3 questions assessing how dependent participants feel when taking TP. Questions are scored on a 5-point Likert scale, ranging from 0 ("Never") to 4 ("Very Often"). Higher scores indicate higher feelings of dependence.

    Time frame: Days 29, 31, 36

  73. EMA Mood Assessments

    To assess the effect of TP on mood compared to placebo. A non-validated questionnaire consisting of 13 questions assessing the participants emotional and mental/physical states they are feeling "right now." This questionnaire uses bipolar visual analogue scales in which participants how they feel "right now" on lines between two opposite feelings or physical sensations.

    Time frame: Days 4, 8, 12, 16, 20, 24, 28, 30, 32, 34

  74. Study Product Perception & Attitude Survey

    To assess the effect of TP on study product perceptions and attitudes compared to placebo. A non-validated questionnaire consisting of multiple items assessing participants' subjective experiences with the study product, including effects on daily functioning, energy, sleep, mood, stress/anxiety, focus, pain, muscle recovery, tolerability, and product quality. Items are scored on a 5-point Likert scale ranging from "Strongly Disagree" to "Strongly Agree." Higher scores indicate more favorable perceptions of the study product (except for the side-effects item, where higher scores indicate greater perceived side effects).

    Time frame: Days 15 and 29

  75. Appraisal of Effects Survey

    To assess participant-reported perceptions of the effects of the study product compared to placebo. A non-validated, self-administered questionnaire consisting of multiple items assessing participants' subjective experiences with the study product, including overall effect on how they feel, liking of the product, pain, muscle fatigue, mental focus/concentration, and calmness/stress. Items are scored using a 100-point visual analogue scale ranging from "Not at all" (0) to "Extremely" (100). Higher scores indicate greater perceived effects of the study product.

    Time frame: Days 2, 6, 10, 14, 18, 22, and 26.

  76. Safety Assessment - Incidence of Treatment-Emergent Adverse Events

    Number and percentage of participants experiencing treatment-emergent adverse events from first dose through follow-up.

    Time frame: Screening through Day 36 and follow-up phone call (approximately 8 weeks)

  77. Safety Assessment - Vital Signs (Heart Rate)

    Change in Heart Rate (beats per minute) from baseline to each study visit.

    Time frame: Screening through Day 36

  78. Safety Assessment - Vital Signs (Blood Pressure)

    Change in Blood Pressure (mmHg) from baseline to each study visit.

    Time frame: Screening through Day 36

  79. Safety Assessment - Vital Signs (Respiratory Rate)

    Change in Respiratory Rate (breaths per minute) from baseline to each study visit.

    Time frame: Screening through Day 36

  80. Safety Assessment - Vital Signs (Oxygen Saturation)

    Change in Oxygen Saturation (SpO₂ %) from baseline to each study visit.

    Time frame: Screening through Day 36

  81. Safety Assessment - Clinical Laboratory Test (Hematology - Hemoglobin)

    To assess the safety of TP through the change from baseline to each study visit in hemoglobin (g/L).

    Time frame: Screening through Day 36

  82. Safety Assessment - Clinical Laboratory Test (Hematology - Hematocrit)

    To assess the safety of TP through the change from baseline to each study visit in hematocrit (%).

    Time frame: Screening through Day 36

  83. Safety Assessment - Clinical Laboratory Test (Hematology - Red Blood Cell Count)

    To assess the safety of TP through the change from baseline to each study visit in red blood cell count (×10E\^12/L).

    Time frame: Screening through Day 36

  84. Safety Assessment - Clinical Laboratory Test (Hematology - Red Cell Distribution Width)

    To assess the safety of TP through the change from baseline to each study visit in red cell distribution width.

    Time frame: Screening through Day 36

  85. Safety Assessment - Clinical Laboratory Test (Hematology - Mean Corpuscular Volume)

    To assess the safety of TP through the change from baseline to each study visit in mean corpuscular volume (fL).

    Time frame: Screening through Day 36

  86. Safety Assessment - Clinical Laboratory Test (Hematology - Mean Corpuscular Hemoglobin)

    To assess the safety of TP through the change from baseline to each study visit in mean corpuscular hemoglobin (pg).

    Time frame: Screening through Day 36

  87. Safety Assessment - Clinical Laboratory Test (Hematology - Mean Corpuscular Hemoglobin Concentration)

    To assess the safety of TP through the change from baseline to each study visit in mean corpuscular hemoglobin concentration (g/L).

    Time frame: Screening through Day 36

  88. Safety Assessment - Clinical Laboratory Test (Hematology - White Blood Cell Count)

    To assess the safety of TP through the change from baseline to each study visit in white blood cell count (×10\^9/L).

    Time frame: Screening through Day 36

  89. Safety Assessment - Clinical Laboratory Test (Hematology - Neutrophil Count)

    To assess the safety of TP through the change from baseline to each study visit in Neutrophil Count (×10\^9/L).

    Time frame: Screening through Day 36

  90. Safety Assessment - Clinical Laboratory Test (Hematology - Eosinophil Count)

    To assess the safety of TP through the change from baseline to each study visit in eosinophil count (×10\^9/L).

    Time frame: Screening through Day 36

  91. Safety Assessment - Clinical Laboratory Test (Hematology - Basophil Count)

    To assess the safety of TP through the change from baseline to each study visit in basophil count (x 10\^9/L).

    Time frame: Screening through Day 36

  92. Safety Assessment - Clinical Laboratory Test (Hematology - Lymphocyte Count)

    To assess the safety of TP through the change from baseline to each study visit in lymphocyte count (×10\^9/L).

    Time frame: Screening through Day 36

  93. Safety Assessment - Clinical Laboratory Test (Hematology - Monocyte Count)

    To assess the safety of TP through the change from baseline to each study visit in hemoglobin (×10\^9/L).

    Time frame: Screening through Day 36

  94. Safety Assessment - Clinical Laboratory Test (Hematology - Platelet Count)

    To assess the safety of TP through the change from baseline to each study visit in platelet count (×10\^9/µL).

    Time frame: Screening through Day 36

  95. Safety Assessment - Clinical Laboratory Test (Hematology - Mean Platelet Volume)

    To assess the safety of TP through the change from baseline to each study visit in mean platelet volume (fL).

    Time frame: Screening through Day 36

  96. Safety Assessment - Clinical Laboratory Test (Hematology - Blood Smear Findings)

    To assess the safety of TP through the change from baseline to each study visit in blood smear findings.

    Time frame: Screening through Day 36

  97. Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Blood Urea Nitrogen)

    To assess the safety of TP through the change from baseline to each study visit in blood urea nitrogen (mmol/L).

    Time frame: Screening through Day 36

  98. Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Creatinine)

    To assess the safety of TP through the change from baseline to each study visit in creatinine (umol/L).

    Time frame: Screening through Day 36

  99. Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Estimated Glomerular Filtration Rate)

    To assess the safety of TP through the change from baseline to each study visit in estimated glomerular filtration rate (ml/min/1.7m\^2).

    Time frame: Screening through Day 36

  100. Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Albumin)

    To assess the safety of TP through the change from baseline to each study visit in albumin (g/L).

    Time frame: Screening through Day 36

  101. Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Random Glucose)

    To assess the safety of TP through the change from baseline to each study visit in random glucose (mmol/L).

    Time frame: Screening through Day 36

  102. Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Fasting Glucose)

    To assess the safety of TP through the change from baseline to each study visit in fasting glucose (mmol/L).

    Time frame: Screening through Day 36

  103. Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Total Protein)

    To assess the safety of TP through the change from baseline to each study visit in total protein (g/L).

    Time frame: Screening through Day 36

  104. Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Sodium)

    To assess the safety of TP through the change from baseline to each study visit in Sodium (mmol/L).

    Time frame: Screening through Day 36

  105. Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Potassium)

    To assess the safety of TP through the change from baseline to each study visit in Potassium (mmol/L).

    Time frame: Screening through Day 36

  106. Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Chloride)

    To assess the safety of TP through the change from baseline to each study visit in Chloride (mmol/L).

    Time frame: Screening through Day 36

  107. Safety Assessment - Clinical Laboratory Test (Liver Function Test - Aspartate Transaminase)

    To assess the safety of TP through the change from baseline to each study visit in Aspartate Transaminase (AST) in U/L.

    Time frame: Screening through Day 36

  108. Safety Assessment - Clinical Laboratory Test (Liver Function Test - Alanine Transaminase)

    To assess the safety of TP through the change from baseline to each study visit in Alanine Transaminase (ALT) in U/L.

    Time frame: Screening through Day 36

  109. Safety Assessment - Clinical Laboratory Test (Liver Function Test - Gamma-Glutamyl Transferase)

    To assess the safety of TP through the change from baseline to each study visit in Gamma-Glutamyl Transferase (GGT) in U/L.

    Time frame: Screening through Day 36

  110. Safety Assessment - Clinical Laboratory Test (Liver Function Test - Total Bilirubin)

    To assess the safety of TP through the change from baseline to each study visit in Total Bilirubin in µmol/L.

    Time frame: Screening through Day 36

  111. Safety Assessment - Clinical Laboratory Test (Liver Function Test - Direct Bilirubin)

    To assess the safety of TP through the change from baseline to each study visit in Direct Bilirubin in µmol/L.

    Time frame: Screening through Day 36

  112. Safety Assessment - Clinical Laboratory Test (Liver Function Test - Total Bile Acids)

    To assess the safety of TP through the change from baseline to each study visit in Total Bile Acids in µmol/L.

    Time frame: Screening through Day 36

  113. Safety Assessment - Clinical Laboratory Test (Liver Function Test - Alkaline Phosphatase)

    To assess the safety of TP through the change from baseline to each study visit in Alkaline Phosphatase (ALP) in U/L.

    Time frame: Screening through Day 36

  114. Safety Assessment - Clinical Laboratory Test (Liver Function Test - Prothrombin Time)

    To assess the safety of TP through the change from baseline to each study visit in Prothrombin Time (PT) in seconds.

    Time frame: Screening through Day 36

  115. Safety Assessment - Clinical Laboratory Test (Liver Function Test - International Normalized Ratio)

    To assess the safety of TP through the change from baseline to each study visit in International Normalized Ratio (INR).

    Time frame: Screening through Day 36

  116. Safety Assessment - Clinical Laboratory Test (Thyroid Function Test - Thyroid-Stimulating Hormone)

    To assess the safety of TP through the change from baseline to each study visit in Thyroid-Stimulating Hormone (TSH) in mIU/L.

    Time frame: Screening through Day 36

  117. Safety Assessment - Clinical Laboratory Test (Thyroid Function Test - Triiodothyronine)

    To assess the safety of TP through the change from baseline to each study visit in Triiodothyronine (T3) in nmol/L.

    Time frame: Screening through Day 36

  118. Safety Assessment - Clinical Laboratory Test (Thyroid Function Test - Thyroxine )

    To assess the safety of TP through the change from baseline to each study visit in Thyroxine (T4) in ug/dL.

    Time frame: Screening through Day 36

  119. Safety Assessment - Clinical Laboratory Test (Lipid Panel - Total Cholesterol)

    To assess the safety of TP through the change from baseline to each study visit in Total Cholesterol in mmol/L.

    Time frame: Screening through Day 36

  120. Safety Assessment - Clinical Laboratory Test (Lipid Panel - HDL)

    To assess the safety of TP through the change from baseline to each study visit in high-density lipoprotein (HDL) cholesterol in mmol/L.

    Time frame: Screening through Day 36

  121. Safety Assessment - Clinical Laboratory Test (Lipid Panel - LDL)

    To assess the safety of TP through the change from baseline to each study visit in low-density lipoprotein (LDL) cholesterol in mmol/L.

    Time frame: Screening through Day 36

  122. Safety Assessment - Clinical Laboratory Test (Lipid Panel - HDL:LDL Ratio)

    To assess the safety of TP through the change from baseline to each study visit in HDL:LDL Ratio.

    Time frame: Screening through Day 36

  123. Safety Assessment - Clinical Laboratory Test (Lipid Panel - Triglycerides)

    To assess the safety of TP through the change from baseline to each study visit in Triglycerides in mmol/L.

    Time frame: Screening through Day 36

  124. Safety Assessment: Change in Subjective Opiate Withdrawal Scale (SOWS)

    To test the safety of TP by assessing the change in SOWS. This validated questionnaire is used to assess participants intensity of potential opioid withdrawal symptoms. Items are scored on a 5-point Likert scale ranging from 0 ('Not at all') to 4 ('Extremely'). Higher scores indicate higher potential withdrawal symptoms.

    Time frame: Day 1, Day 29, and follow-up visits (Day 31 and Day 36)

  125. Safety Assessment: Change in Clinical Opiate Withdrawal Scale (COWS)

    To test the safety of TP by assessing the change in COWS. This validated questionnaire is used to assess common signs and symptoms of opiate withdrawal. Items are scored from 0 to 48. Higher scores indicate higher withdrawal symptoms.

    Time frame: Day 29, and follow-up visits (Day 31 and Day 36)

07

Study locations

1 of 1 sites recruiting
  • ApexTrials
    Guelph, Ontario N1G 0B4, Canada
    Recruiting
    • Katie Keene, H.BSc., CCRP · Contactkkeene@apextrials.com · 226-706-2545
    • Anthony Bier, MD, CCFP(EM) · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jan 2027, 9 months after the start.

Of 105 industry-sponsored interventional studies with no phase under Anxiety Disorders, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 16. This study's planned 9 months is above that.

Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Sep 2026 → Jan 2027 and completion Oct 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 13, 2026
StartActual
Mar 7, 2026
Primary completionEst.
Jan 4, 2027was Sep 2026
CompletionEst.
Jan 14, 2027was Oct 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Jan 4, 2027
Nov 20, 2026
Study completion
Oct 14, 2026→Jan 14, 2027
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Primary completion Sep 30, 2026→Jan 4, 2027
    Study completion Oct 14, 2026→Jan 14, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07469527
Lead sponsor
Botanic Tonics, LLC
Collaborators
Nutrasource Pharmaceutical and Nutraceutical Services, Inc.
Responsible party
Sponsor
First posted
Mar 13, 2026
Start date
Mar 7, 2026
Primary completion
Jan 4, 2027 (estimated)
Completion
Jan 14, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Ambreen Atif, MD
Contact
aatif@nutrasource.ca
519-341-3367 ext. 129
Stephanie Recker
Contact
srecker@nutrasource.ca
519-341-3367 ext. 109
Ramsey Atallah
study director · Botanic Tonics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion